



# Exercise ventilatory inefficiency in heart failure: some fresh news into the roadmap of heart failure with preserved ejection fraction phenotyping

Piergiuseppe Agostoni<sup>1,2\*</sup> and Marco Guazzi<sup>3</sup>

<sup>1</sup>Cardiology Monzino Center, IRCCS, Milan, Italy; <sup>2</sup>Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Milan, Italy; and

<sup>3</sup>University Cardiology Department, University of Milan, Department of Biomedical Sciences for Health, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy

**This article refers to ‘Physiological dead space and arterial carbon dioxide contributions to exercise ventilatory inefficiency in patients with reduced or preserved ejection fraction heart failure’, by E.H. Van Iterson *et al.*, published in this issue on pages 1675–1685.**

A progressive increase in exercise ventilation (VE) is vital to the efficiency of gas exchange and its related abnormalities have been long recognized as a matter of concern in heart failure (HF).<sup>1</sup>

At sea level (normobaric normoxia) VE is regulated by the carbon dioxide production ( $VCO_2$ ), the dead space to tidal volume ratio (VD/VT), and the  $CO_2$  partial pressure ( $PaCO_2$ ), which are the final bioproduct of muscle activity, waste VE, and chemoreflex regulation, respectively. Accordingly, VE increases during exercise due to the progressive release of  $CO_2$  and their relationship is determined by two sources based on the modified alveolar equation (Figure 1A): the increased VE, which is required to overcome a large dead space to maintain a normal  $PaCO_2$ , and the enhanced neural drive to VE which yields  $PaCO_2$  levels below what is normally expected. In healthy individuals, for low to moderate intensity of work, the VE response is tightly regulated by the  $PaCO_2$ , whereas at higher work intensities, VE is more affected by the amount of VD/VT and by the development of lactic acidosis and  $H^+$  production from anaerobic prevailing metabolism. In its turn, VD/VT is highly dependent on respiratory rate. Thus, VD/VT ratio and  $PaCO_2$  are the two reference variables for exploring the pathways involved in a deranged ventilatory response.<sup>2</sup>

The physiological increase in exercise VE during a ramp exercise protocol to maximum is defined by four distinct phases: the first up to the ventilatory threshold, also called the anaerobic threshold; the second between the 1st ventilatory threshold and the respiratory compensation point (2nd ventilatory threshold);

the third up to peak exercise. In a few highly performing subjects a fourth phase is observed around peak exercise (Figure 1B). The mediators of these phases are  $VO_2$ ,  $VCO_2$ , unbuffered acidosis, and thermal dispersion, respectively. All these factors are, at least in part, under the control of the sympathetic nervous system.


The net result of changes in VE during exercise is defined by the  $VE/VCO_2$  relationship that in normal conditions is characterized by an intercept at 4–5 L and for an approximately 1 L of  $VCO_2$  by 23–25 L/min VE (Figure 1B). Overall,  $VE/VCO_2$  reflects VE efficiency, which is similarly described when assessing the ratio at determined points (1st ventilatory threshold or lower ratio) or the slope.<sup>3</sup>

In HF, there are a number of factors that may mutually and negatively interact impairing this relationship during exercise: intrinsic pulmonary vascular<sup>4</sup> and non-vascular disease,<sup>5–7</sup> impaired neural<sup>8</sup> control of VE, and early incurrence of acidosis (Figure 1C).<sup>7</sup> Overall, it is now well established that an excessive VE during exercise, i.e. steep  $VE/VCO_2$  slope, is the net result of the deregulated cardiorespiratory reflex control and a manifestation of structural changes in the lung that impair ventilation (V)/perfusion (Q) matching. In their pioneering report, Wasserman *et al.*<sup>5</sup> showed that in HF with reduced ejection fraction (HFrEF) VE is increased for a given work rate, even double than in normal subjects.

What are the reasons and related interpretations? Again, from a physiological standpoint, it is relevant to define ‘hyperpnoea’ (increase in VE response at normal  $PaCO_2$ ) compared with ‘hyperventilation’ (increase in VE at  $PaCO_2$  levels below normal). In the former case, VD/VT is the cause of the increased VE for a given  $VCO_2$  while reflex, sympathetic-induced, increase in VE is present, alone or combined with VD/VT increase, in the second case. In HFrEF it has been shown that 8%, 47%, and 45% of VE increase is due to  $PaCO_2$ ,  $VCO_2$ , and VD/VT, respectively.<sup>5</sup> This,

The opinions expressed in this article are not necessarily those of the Editors of the *European Journal of Heart Failure* or of the European Society of Cardiology. doi: 10.1002/ejhf.913

\*Corresponding author. Centro Cardiologico Monzino IRCCS, Istituto di Cardiologia Università di Milano, via Parea 4, 20138 Milan, Italy. Tel: +39 02 58002 299, Fax: +39 02 504667, Email: piergiuseppe.agostoni@unimi.it



**Figure 1** (A) The modified alveolar equation and its determinants. (B) Description of ventilation vs. carbon dioxide production increase during exercise. Ventilation increments are driven by CO<sub>2</sub> changes in the deoxygenated blood. A difference between alveolar ventilation and effective ventilation increase is mediated by the extent of dead space. After a linear increase in the initial and intermediate phases, a change in slope occurs due to isocapnic compensation for incoming acidosis. At the end of exercise, a further steepening occurs as a result of respiratory compensation. Adapted with permission from *Principles of Exercise Testing and Interpretation*, Wasserman *et al.*,<sup>30</sup> Lippincott Williams & Wilkins ©2011. (C) Mechanisms responsible for the increase in ventilation/carbon dioxide production slope during exercise in heart failure. PaCO<sub>2</sub>, CO<sub>2</sub> partial pressure; PVR, pulmonary vascular resistance; VA, alveolar ventilation; VCO<sub>2</sub>, carbon dioxide production; VD, dead space; VE, ventilation; VT, tidal volume.

along with other evidence, has made it axiomatic that HF patients display a sort of mixed response due to either hyperpnoea or hyperventilation.

Ultimately, an increased VE/VCO<sub>2</sub> slope has long been recognized as a major determinant of exercise limitation in HF and one of the most powerful predictors of outcome available.<sup>9</sup> Unequivocal evidence on this parameter has yielded to the formulation of a subdivision of four classes to be used and integrated in a multiparametric process of clinical decision-making.<sup>10–12</sup> Thus, the precise knowledge about what factor disturbs the exercise VE/VCO<sub>2</sub> slope translates into a better potential for treatment.<sup>13</sup>

Of note, most of the findings regarding the pathophysiological and clinical insights on VE/VCO<sub>2</sub> slope have been obtained in a population of HFrEF.<sup>14</sup>

In the present issue of the Journal, Van Iterson *et al.*<sup>15</sup> report an elegant set of observations on the two pathophysiological contributors to impaired VE efficiency during exercise, extending the evidence to HF with preserved ejection fraction (HFpEF) patients. Interestingly, a comparative evaluation of HFrEF vs. HFpEF by cardiopulmonary exercise testing with PaCO<sub>2</sub> sampling via radial

arterial catheterization showed an impaired VE efficiency in both groups, despite a higher level of VE/VCO<sub>2</sub> slope in HFrEF, and a different pattern in VD/VT and PaCO<sub>2</sub>.

At rest, HFpEF, compared with HFrEF, displayed an end-tidal CO<sub>2</sub> (PETCO<sub>2</sub>) significantly lower (for the same respiratory rate), consistent with a tendency toward a lower PaCO<sub>2</sub> and a higher VD/VT, which is indicative of more ventilated but not perfused lung areas. The same was observed at peak exercise with the new finding that HFpEF is accompanied by a predominant impairment of VD/VT and a quite normal PaCO<sub>2</sub>, suggestive, from a physiological point of view, of hyperpnoea. This pattern clearly differentiates HFpEF from HFrEF whose abnormal VE response is also driven by a low PaCO<sub>2</sub> and increased chemoreflex activity (hyperventilation).<sup>16–18</sup> The unquestionable strength of the paper is the reliable measurement of VD/VT by incorporating into the formula the invasively obtained PaCO<sub>2</sub> and avoiding the underestimation when calculated by PETCO<sub>2</sub>.<sup>19</sup>

Some considerations are necessary to better highlight the present findings. Is there enough evidence for abnormal VE to play a critical role in HFpEF? How could the differences in VE

determinants be convincingly explained and what are the potential reasons for a prevailing VD/VT-related mechanism in HFpEF?

HFpEF definition applies to a garden-variety of clinical phenotypes. Previous studies have reported lower levels of inefficient VE compared with the present population.<sup>20,21</sup> Nonetheless, the actual population appears to be in a quite peculiar advanced stage of the syndrome as suggested by the high rate (74%) of Weber peak  $\text{VO}_2$  class D.

As VD/VT depends on  $V/Q$  mismatch, valid measures of  $V/Q$  matching are helpful for the identification of underlying mechanisms and provide clear implications in terms of interventions. Actually, measures of alveolar gas diffusion would have been of help in this respect. Nonetheless, the authors make a strong argument on the minimal effect that a mild reduction in alveolar gas diffusion (around 20% based on a previous case series) would have on  $\text{CO}_2$  transfer even in the presence of a low perfusion, while impacting the alveolar–arterial  $\text{O}_2$  difference. Thus, a lung vascular disease, potentially induced by the systemic proinflammatory state<sup>22</sup>, may be suspected to play the major role in the present HFpEF population. Very likely, this assertion would have been less speculative in the case of a direct lung  $V/Q$  assessment<sup>23</sup> along with a thorough definition of the underlying pulmonary haemodynamics and right ventricular function to pulmonary circulation coupling.<sup>24</sup>

Considering the different underlying pathophysiology, with a prevailing higher reflex-induced inefficiency of VE in HFpEF as the major reason for exercise hyperventilation and a high VD/VT as the major cause of hyperpnoea in HFpEF, should we start to consider ventilatory abnormalities during exercise a more focused target of therapy and treat them accordingly? Evidence is lacking but some speculation may derive from the observed physiological ventilatory adaptations obtained at high altitude, where hypoxia (and the associated high  $\text{VE}/\text{VCO}_2$  slope) can be partially corrected by a voluntarily imposed high tidal volume at low VE frequencies.<sup>25</sup> This way of breathing is typical of some relaxing activities such as rosarium, yoga, and listening to music that might overall benefit VE efficiency, at least in HFpEF.<sup>26,27</sup> In HFpEF, the recent greater molecular understanding of endothelial damage and oxidative stress due to the proinflammatory state would imply the concept of a pulmonary microvessel vasculopathy susceptible to benefits by interventions targeting the impaired nitric oxide–cGMP bioavailability pathway by improving the regional lung perfusion and, for instance, the VD/VT pattern during exercise.<sup>28,29</sup>

In conclusion, evidence provided by Van Iterson *et al.*<sup>15</sup> refreshes some knowledge on the ventilatory mediators of exercise intolerance and remarkably enriches the picture, especially prospecting for new insights on patients with HFpEF. Findings support the hypothesis that HFpEF and HFrEF may be two distinct entities also in terms of ventilatory response to physical challenge. The roadmap of HFpEF phenotyping is intriguingly moving forward, hopefully in the right direction.

**Conflict of interest:** none declared.

## References

- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016;**18**:891–975.
- Wasserman K. Coupling of external to cellular respiration during exercise: the wisdom of the body revisited. *Am J Physiol* 1994;**266**:E519–539.
- Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, Arena R, Fletcher GF, Forman DE, Kitzman DW, Lavie CJ, Myers J; European Association for Cardiovascular Prevention & Rehabilitation; American Heart Association. EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. *Circulation* 2012;**126**:2261–2274.
- Lewis GD, Shah RV, Pappagianopoulos PP, Systrom DM, Semigran MJ. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. *Circ Heart Fail* 2008;**1**:227–233.
- Wasserman K, Zhang YY, Gitt A, Belardinelli R, Koike A, Lubarsky L, Agostoni PG. Lung function and exercise gas exchange in chronic heart failure. *Circulation* 1997;**96**:2221–2227.
- Wensel R, Georgiadou P, Francis DP, Bayne S, Scott AC, Genth-Zotz S, Anker SD, Coats AJ, Piepoli MF. Differential contribution of dead space ventilation and low arterial  $\text{pCO}_2$  to exercise hyperpnea in patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 2004;**93**:318–323.
- Guazzi M, Reina G, Tumminello G, Guazzi MD. Exercise ventilation inefficiency and cardiovascular mortality in heart failure: the critical independent prognostic value of the arterial  $\text{CO}_2$  partial pressure. *Eur Heart J* 2005;**26**:472–480.
- Piepoli M, Clark AL, Volterrani M, Adamopoulos S, Sleight P, Coats AJ. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. *Circulation* 1996;**93**:940–952.
- Chua TP, Ponikowski P, Harrington D, Anker SD, Webb-Peploe K, Clark AL, Poole-Wilson PA, Coats AJ. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. *J Am Coll Cardiol* 1997;**29**:1585–1590.
- Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, Guazzi M. Development of a ventilatory classification system in patients with heart failure. *Circulation* 2007;**115**:2410–2417.
- Agostoni P, Corra U, Cattadori G, Veglia F, La Gioia R, Scardovi AB, Emdin M, Metra M, Sinagra G, Limongelli G, Raimondo R, Re F, Guazzi M, Belardinelli R, Parati G, Magri D, Fiorentini C, Mezzani A, Salvioni E, Scrutinio D, Ricci R, Bettari L, Di Lenarda A, Pastormerlo LE, Pacileo G, Vaninetti R, Apostolo A, Iorio A, Paolillo S, Palermo P, Contini M, Confalonieri M, Giannuzzi P, Passantino A, Cas LD, Piepoli MF, Passino C; MECKI Score Research Group. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. *Int J Cardiol* 2013;**167**:2710–2718.
- Agostoni P, Corra U, Cattadori G, Veglia F, Battaia E, La Gioia R, Scardovi AB, Emdin M, Metra M, Sinagra G, Limongelli G, Raimondo R, Re F, Guazzi M, Belardinelli R, Parati G, Magri D, Fiorentini C, Ciccoira M, Salvioni E, Giovannardi M, Mezzani A, Scrutinio D, Di Lenarda A, Mantegazza V, Ricci R, Apostolo A, Iorio A, Paolillo S, Palermo P, Contini M, Vassanelli C, Passino C, Piepoli MF. Prognostic value of indeterminate anaerobic threshold in heart failure. *Circ Heart Fail* 2013;**6**:977–987.
- Contini M, Apostolo A, Cattadori G, Paolillo S, Iorio A, Bertella E, Salvioni E, Alimento M, Farina S, Palermo P, Loguerio M, Mantegazza V, Karsten M, Sciomer S, Magri D, Fiorentini C, Agostoni P. Multiparametric comparison of CARvedilol, vs. Nebivolol, vs. Bisoprolol in moderate heart failure: the CARNEBI trial. *Int J Cardiol* 2013;**168**:2134–2140.
- Guazzi M. Cardiopulmonary exercise testing in heart failure preserved ejection fraction: time to expand the paradigm in the prognostic algorithm. *Am Heart J* 2016;**174**:164–166.
- Van Iterson EH, Johnson BD, Borlaug BA, Olson TP. Physiological dead space and arterial carbon dioxide contributions to exercise ventilatory inefficiency in patients with reduced or preserved ejection fraction heart failure. *Eur J Heart Fail* 2017;**19**:1675–1685.
- Gargiulo P, Apostolo A, Perrone-Filardi P, Sciomer S, Palange P, Agostoni P. A non invasive estimate of dead space ventilation from exercise measurements. *PLoS One* 2014;**9**:e87395.
- Apostolo A, Laveneziana P, Palange P, Agalbatto C, Molle R, Popovic D, Bussotti M, Internullo M, Sciomer S, Bonini M, Alencar MC, Godinas L, Arbex F, Garcia G, Neder JA, Agostoni P. Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure. *Int J Cardiol* 2015;**189**:134–140.
- Paolillo S, Pellegrino R, Salvioni E, Contini M, Iorio A, Bovis F, Antonelli A, Torchio R, Gulotta C, Locatelli A, Agostoni P. Role of alveolar beta2-adrenergic

- receptors on lung fluid clearance and exercise ventilation in healthy humans. *PLoS One* 2013;**8**:e61877.
19. Guazzi M, Marenzi G, Assanelli E, Perego GB, Cattadori G, Doria E, Agostoni PG. Evaluation of the dead space/tidal volume ratio in patients with chronic congestive heart failure. *J Card Fail* 1995;**1**:401–408.
  20. Sugimoto T, Bandera F, Generati G, Alfonzetti E, Bussadori C, Guazzi M. Left atrial function dynamics during exercise in heart failure: pathophysiological implications on the right heart and exercise ventilation inefficiency. *JACC Cardiovasc Imaging* 2017;**10**(10 Pt B):1253–1264.
  21. Shafiq A, Brawner CA, Aldred HA, Lewis B, Williams CT, Tita C, Schairer JR, Ehrman JK, Velez M, Selektor Y, Lanfear DE, Keteyian SJ. Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry Ford Hospital CardioPulmonary EXercise Testing (FIT-CPX) project. *Am Heart J* 2016;**174**:167–172.
  22. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. *Circulation* 2016;**134**:73–90.
  23. Cao JJ, Wang Y, McLaughlin J, Rhee P, Passick M, Ngai N, Cheng J, Gulotta RJ, Berke AD, Petrossian GA, Reichel N. Effects of hemodynamics on global and regional lung perfusion: a quantitative lung perfusion study by magnetic resonance imaging. *Circ Cardiovasc Imaging* 2012;**5**:693–699.
  24. Guazzi M, Dixon D, Labate V, Beussink-Nelson L, Bandera F, Cuttica MJ, Shah SJ. RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes. *JACC Cardiovasc Imaging* 2017;**10**(10 Pt B):1211–1221.
  25. Bilo G, Revera M, Bussotti M, Bonacina D, Styczkiewicz K, Caldara G, Giglio A, Faini A, Giuliano A, Lombardi C, Kawecka-Jaszcz K, Mancina G, Agostoni P, Parati G. Effects of slow deep breathing at high altitude on oxygen saturation, pulmonary and systemic hemodynamics. *PLoS One* 2012;**7**:e49074.
  26. Bernardi L, Sleight P, Bandinelli G, Cencetti S, Fattorini L, Wdowczyk-Szulc J, Lagi A. Effect of rosary prayer and yoga mantras on autonomic cardiovascular rhythms: Comparative study. *BMJ* 2001;**323**:1446–1449.
  27. Parati G, Malfatto G, Boarin S, Branzi G, Caldara G, Giglio A, Bilo G, Ongaro G, Alter A, Gavish B, Mancina G. Device-guided paced breathing in the home setting: Effects on exercise capacity, pulmonary and ventricular function in patients with chronic heart failure: a pilot study. *Circ Heart Fail* 2008;**1**:178–183.
  28. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. *Circulation* 2011;**124**:164–174.
  29. Reddy YNV, Lewis GD, Shah SJ, LeWinter M, Semigran M, Davila-Roman VG, Anstrom K, Hernandez A, Braunwald E, Redfield MM, Borlaug BA. INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): rationale and design. *Circ Heart Fail* 2017;**10**:e003862.
  30. Wasserman K, Hansen JE, Sue DY, Whipp BJ, Casaburi R. *Principles of Exercise Testing and Interpretation: Including Pathophysiology and Clinical Applications*. Philadelphia: Lippincott Williams & Wilkins; 2006.